Overview

A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.

Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is non-inferior compared to the standard weight-based formula.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Insulin
Insulin, Globin Zinc